Lessons from intensified surveillance of viral hepatitis A, Israel, 2017 and 2018

Yael Gozlan(Sheba Medical Center), Orna Mor(Sheba Medical Center), Inbal Fuchs(Clalit Health Services), Etti Levy Dahary(Clalit Health Services), Efrat Asulin(Sheba Medical Center), Hadar Volnowitz(Sheba Medical Center), Rivka Rich(Israel Ministry of Health), Ilana Goldiner(Tel Aviv Sourasky Medical Center), Moran Szwarcwort Cohen(Rambam Health Care Campus), Itay Bar-Or(Sheba Medical Center), Orit Picard(Sheba Medical Center), Yonat Shemer(Soroka Medical Center), Emilia Anis(Israel Ministry of Health), Licita Schreiber(Maccabi Healthcare Services), Orit Rozenberg(Emek Medical Center), Michal Savion(Israel Ministry of Health), Ella Mendelson(Tel Aviv University)
Eurosurveillance
February 11, 2021
10.2807/1560-7917.es.2021.26.6.2000001
Cited by 10

Related Papers

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
|The Lancet|2021|1.7k
Rethinking wastewater risks and monitoring in light of the COVID-19 pandemic
|Nature Sustainability|2020|318
Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021
|Eurosurveillance|2021|281
Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch
|Wellcome Open Research|2021|228
Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2
|Wellcome Open Research|2021|210